MorphoSys AG MOR-DE:XETRA

*Data is delayed | EUR
Last | 07/01/22 CEST
19.39quote price arrow up+0.62 (+3.30%)
Volume
98,710
52 week range
16.45 - 69.00
Loading...
  • Open18.57
  • Day High19.40
  • Day Low18.48
  • Prev Close18.77
  • 52 Week High69.00
  • 52 Week High Date06/29/21
  • 52 Week Low16.45
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap678.11M
  • Shares Out34.15M
  • 10 Day Average Volume179,273.42
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-41.84

KEY STATS

  • Open18.57
  • Day High19.40
  • Day Low18.48
  • Prev Close18.77
  • 52 Week High69.00
  • 52 Week High Date06/29/21
  • 52 Week Low16.45
  • 52 Week Low Date05/12/22
  • Market Cap678.11M
  • Shares Out34.15M
  • 10 Day Average Volume179,273.42
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-41.84

RATIOS/PROFITABILITY

  • EPS (TTM)-17.41
  • P/E (TTM)-1.11
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On MorphoSys AG

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery...
Sung Lee
Chief Financial Officer, Member of the Management Board
Address
Semmelweisstr. 7
Planegg
82152
Germany